Contact Us
Drug Search Results
More Filters [+]

Nonacog alfa

Alternative Names: nonacog alfa
Latest Update: 2024-11-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FIX Analogue

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Italy | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Spain | Taiwan | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nonacog alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hemophilia B|Hemophilia A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2020-004430-38

P4

Active, not recruiting

Hemophilia B

2021-03-19

B1821059

P4

Completed

Hemophilia B|Hemophilia A

2020-09-24

2015-003027-61

P1

Unknown status

Unknown

2017-10-29

2016-000765-22

P4

Completed

Hemophilia B

2017-09-14

Recent News Events

Date

Type

Title

05/01/2024

PubMed

 Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.

10/01/2023

PubMed

 Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India.

03/11/2023

PubMed

 Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.

06/08/2021

News Article

 Global Hemophilia B Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions